肌肉萎缩症的治疗进展。
Therapeutic advances in muscular dystrophy.
机构信息
Center for Genetic Muscle Disorders, Kennedy Krieger Institute, Baltimore, MD; Departments of Neurology, Johns Hopkins School of Medicine, Baltimore, MD.
出版信息
Ann Neurol. 2013 Sep;74(3):404-11. doi: 10.1002/ana.23989.
Abstract
The muscular dystrophies comprise a heterogeneous group of genetic disorders that produce progressive skeletal muscle weakness and wasting. There has been rapid growth and change in our understanding of these disorders in recent years, and advances in basic science are being translated into increasing numbers of clinical trials. This review will discuss therapeutic developments in 3 of the most common forms of muscular dystrophy: Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy. Each of these disorders represents a different class of genetic disease (monogenic, epigenetic, and repeat expansion disorders), and the approach to therapy addresses the diverse and complex molecular mechanisms involved in these diseases. The large number of novel pharmacologic agents in development with good biologic rationale and strong proof of concept suggests there will be an improved quality of life for individuals with muscular dystrophy.
摘要
肌肉萎缩症包括一组异质性遗传疾病，这些疾病会导致进行性骨骼肌无力和萎缩。近年来，我们对这些疾病的认识有了迅速的发展和变化，基础科学的进步正在转化为越来越多的临床试验。本综述将讨论 3 种最常见的肌肉萎缩症的治疗进展：杜氏肌营养不良症、面肩肱型肌营养不良症和强直性肌营养不良症。这些疾病中的每一种都代表着不同类型的遗传疾病（单基因、表观遗传和重复扩展疾病），治疗方法针对这些疾病中涉及的不同且复杂的分子机制。有大量新型药物制剂正在开发中，具有良好的生物学原理和强大的概念验证，这表明肌肉萎缩症患者的生活质量将会提高。
相似文献
1
Therapeutic advances in muscular dystrophy.肌肉萎缩症的治疗进展。
Ann Neurol. 2013 Sep;74(3):404-11. doi: 10.1002/ana.23989.
2
Genetic modifiers of Duchenne and facioscapulohumeral muscular dystrophies.杜氏肌营养不良症和面肩肱型肌营养不良症的基因修饰因子
Muscle Nerve. 2018 Jan;57(1):6-15. doi: 10.1002/mus.25953. Epub 2017 Sep 22.
3
The muscular dystrophies.肌肉萎缩症。
Semin Neurol. 2012 Jul;32(3):255-63. doi: 10.1055/s-0032-1329199. Epub 2012 Nov 1.
4
Pharmacological therapies for muscular dystrophies.肌肉萎缩症的药物治疗。
Curr Opin Neurol. 2012 Oct;25(5):604-8. doi: 10.1097/WCO.0b013e328357f44c.
5
Facioscapulohumeral muscular dystrophy.面肩肱型肌营养不良症
Neurotherapeutics. 2008 Oct;5(4):601-6. doi: 10.1016/j.nurt.2008.07.005.
6
A hospital based epidemiological study of genetically determined muscle disease in south western Norway.挪威西南部基于医院的遗传性肌肉疾病的流行病学研究。
Neuromuscul Disord. 2020 Mar;30(3):181-185. doi: 10.1016/j.nmd.2020.01.006. Epub 2020 Feb 4.
7
New therapies in muscular dystrophies.肌肉萎缩症的新疗法。
Neurol Sci. 2000;21(5 Suppl):S919-24. doi: 10.1007/s100720070004.
8
Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.强直性肌营养不良症和面肩肱型肌营养不良症患者的药物依从性
J Neurol. 2016 Dec;263(12):2528-2537. doi: 10.1007/s00415-016-8300-3. Epub 2016 Oct 12.
9
Oral health considerations in muscular dystrophies.肌营养不良症的口腔健康考量
Spec Care Dentist. 2008 Nov-Dec;28(6):243-53. doi: 10.1111/j.1754-4505.2008.00047.x.
10
Hereditary muscular dystrophies and the heart.遗传性肌肉萎缩症与心脏。
Neuromuscul Disord. 2010 Aug;20(8):479-92. doi: 10.1016/j.nmd.2010.04.008.
引用本文的文献
1
Molecular Biology of ACL Graft Healing: Early Mechanical Loading Perspective.前交叉韧带移植物愈合的分子生物学：早期机械负荷视角
Orthop Rev (Pavia). 2025 Jul 26;17:140716. doi: 10.52965/001c.140716. eCollection 2025.
2
Quantitative Structure-Property Relationship Modeling with the Prediction of Physicochemical Properties of Some Novel Duchenne Muscular Dystrophy Drugs.基于定量构效关系模型预测某些新型杜氏肌营养不良症药物的物理化学性质
ACS Omega. 2025 Jan 22;10(4):3640-3651. doi: 10.1021/acsomega.4c08572. eCollection 2025 Feb 4.
3
Reduced myotube diameter induced by combined inhibition of transforming growth factor-β type I receptors Acvr1b and Tgfbr1 is associated with enhanced β1-syntrophin expression.转化生长因子-β I 型受体Acvr1b和Tgfbr1联合抑制诱导的肌管直径减小与β1-肌养蛋白表达增强有关。
J Cell Physiol. 2024 Dec;239(12):e31418. doi: 10.1002/jcp.31418. Epub 2024 Aug 20.
4
A Systematic Review on the Application of Virtual Reality for Muscular Dystrophy Rehabilitation: Motor Learning Benefits.虚拟现实在肌肉萎缩症康复中的应用系统评价：运动学习益处
Life (Basel). 2024 Jun 22;14(7):790. doi: 10.3390/life14070790.
5
Development of a local controlled release system for therapeutic proteins in the treatment of skeletal muscle injuries and diseases.开发局部控释系统治疗骨骼肌损伤和疾病的治疗性蛋白。
Cell Death Dis. 2024 Jul 2;15(7):470. doi: 10.1038/s41419-024-06645-2.
6
Effectiveness of conservative non-pharmacological interventions in people with muscular dystrophies: a systematic review and meta-analysis.保守非药物干预对肌营养不良症患者的疗效：系统评价和荟萃分析。
J Neurol Neurosurg Psychiatry. 2024 Apr 12;95(5):442-453. doi: 10.1136/jnnp-2023-331988.
7
An implantable soft robotic ventilator augments inspiration in a pig model of respiratory insufficiency.一种可植入的软体机器人呼吸机可增强呼吸功能不全猪模型的吸气。
Nat Biomed Eng. 2023 Feb;7(2):110-123. doi: 10.1038/s41551-022-00971-6. Epub 2022 Dec 12.
8
Synthesis of SMT022357 enantiomers and evaluation in a Duchenne muscular dystrophy mouse model.SMT022357对映体的合成及其在杜氏肌营养不良小鼠模型中的评估。
Tetrahedron. 2020 Jan 10;76(2):130819. doi: 10.1016/j.tet.2019.130819.
9
Preliminary Evidences of Safety and Efficacy of Flavonoids- and Omega 3-Based Compound for Muscular Dystrophies Treatment: A Randomized Double-Blind Placebo Controlled Pilot Clinical Trial.基于类黄酮和欧米伽3的化合物治疗肌肉萎缩症的安全性和有效性的初步证据：一项随机双盲安慰剂对照的试点临床试验。
Front Neurol. 2019 Jul 23;10:755. doi: 10.3389/fneur.2019.00755. eCollection 2019.
10
Analysis of Different Device Interactions in a Virtual Reality Task in Individuals With Duchenne Muscular Dystrophy-A Randomized Controlled Trial.杜氏肌营养不良症患者虚拟现实任务中不同设备交互的分析——一项随机对照试验
Front Neurol. 2019 Jan 29;10:24. doi: 10.3389/fneur.2019.00024. eCollection 2019.
本文引用的文献
1
Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect.抗肌萎缩蛋白 T 细胞反应在杜氏肌营养不良症中的表现：患病率和糖皮质激素治疗效果。
Hum Gene Ther. 2013 Sep;24(9):797-806. doi: 10.1089/hum.2013.092.
2
Cost of illness for neuromuscular diseases in the United States.美国神经肌肉疾病的疾病经济负担。
Muscle Nerve. 2014 Mar;49(3):431-8. doi: 10.1002/mus.23942. Epub 2014 Jan 28.
3
Strength training and aerobic exercise training for muscle disease.针对肌肉疾病的力量训练和有氧运动训练。
Cochrane Database Syst Rev. 2013 Jul 9(7):CD003907. doi: 10.1002/14651858.CD003907.pub4.
4
A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays.在多种报告基因检测中，PTC124（Ataluren）缺乏提前终止密码子通读的功效。
PLoS Biol. 2013;11(6):e1001593. doi: 10.1371/journal.pbio.1001593. Epub 2013 Jun 25.
5
Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy.MDA 肌肉疾病研讨会关于杜氏肌营养不良症新生儿筛查的报告。
Muscle Nerve. 2013 Jul;48(1):21-6. doi: 10.1002/mus.23810. Epub 2013 May 29.
6
Exercise in neuromuscular disease.神经肌肉疾病的运动疗法。
Muscle Nerve. 2013 Jul;48(1):3-20. doi: 10.1002/mus.23771. Epub 2013 May 22.
7
The role of fibrosis in Duchenne muscular dystrophy.纤维化在杜氏肌营养不良症中的作用。
Acta Myol. 2012 Dec;31(3):184-95.
8
Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression.衰减无意义介导的 mRNA 降解增强了体内无意义抑制。
PLoS One. 2013 Apr 10;8(4):e60478. doi: 10.1371/journal.pone.0060478. Print 2013.
9
Recent progress in satellite cell/myoblast engraftment -- relevance for therapy.卫星细胞/成肌细胞移植的最新进展——与治疗的相关性。
FEBS J. 2013 Sep;280(17):4281-93. doi: 10.1111/febs.12273. Epub 2013 Apr 24.
10
Gene and cell-mediated therapies for muscular dystrophy.基因和细胞治疗肌肉疾病。
Muscle Nerve. 2013 May;47(5):649-63. doi: 10.1002/mus.23738. Epub 2013 Mar 29.
Zotero 插件